CBD Safety Guide
CBD and Liver Enzymes: What Does Research Report?
A source-led guide to CBD, liver-enzyme findings, study context, and the limits of transferring one safety signal to every product or person.
The short answer
What should you know first?
Liver-enzyme questions are part of CBD safety research, especially in studies of highly purified prescription CBD and specific clinical populations. This guide keeps those findings connected to the exact product, dose, co-medications, population, and monitoring context.
How to read the liver-safety record
Three details that make a liver finding interpretable
Key distinction
Signal versus diagnosis
A study finding about a liver enzyme is not automatically a diagnosis or prediction for every reader.
Key distinction
Study context
Prescription-CBD trials, doses, co-medications, and clinical populations may differ from a consumer product question.
Key distinction
Connected safety questions
Liver findings, medication interactions, product identity, and monitoring context should be read together.
What studies reported
Results worth understanding
These findings belong to the named compound or product, dose, route, population, and outcome. They are not one result for every cannabinoid product or person. Open the PubMed links to inspect the original records.
Randomized human trial
Eight healthy adults exceeded three times the normal limit
After four weeks at 5 mg/kg per day, 8 of 143 CBD participants had ALT or AST above three times the upper limit of normal, compared with 0 of 58 receiving placebo. PubMed 40622698
Open-label phase 1 study
Five of 16 exceeded five times the normal ALT limit
At 1,500 mg per day for about three and a half weeks, 7 of 16 healthy adults developed ALT above normal and 5 exceeded five times the upper limit of normal. PubMed 33022751
Observational human study
Low-dose consumer use showed a different pattern
Among 839 adults using an average of about 50 mg per day, ALT and AST elevation rates were not significantly different from general-population estimates; 0.3% had ALT above three times normal. PubMed 34918948
Systematic review and meta-analysis
Pooled trials found higher liver-signal odds
Across 12 controlled trials, CBD was associated with higher odds of enzyme elevation and drug-induced liver injury. High dose and concurrent antiseizure medicines were identified as risk factors. PubMed 36912195
Research context
Read the evidence in context
Controlled studies show a real liver-enzyme signal
A 2025 randomized trial assigned 201 healthy adults to CBD at 5 mg/kg per day or placebo for four weeks. Eight CBD participants, or 5.6%, developed ALT or AST elevations above three times the upper limit of normal, compared with none receiving placebo. Seven met the study's withdrawal criteria for possible drug-induced liver injury. This makes liver monitoring a substantive research issue rather than a concern limited only to severe epilepsy trials.
Dose and population change what the record looks like
An earlier open-label phase 1 study gave 16 healthy adults 1,500 mg of CBD per day for about three and a half weeks. Seven had ALT above the normal range and five exceeded five times the upper limit of normal. By contrast, an observational study of 839 adults using an average of about 50 mg per day found ALT and AST elevations at rates that were not significantly different from general-population estimates. These designs cannot be treated as interchangeable, but together they show why exposure and study method belong beside every liver result.
A meta-analysis found higher risk in the pooled trial record
A systematic review of 12 controlled trials found greater odds of liver-enzyme elevation and drug-induced liver injury with CBD than placebo. Across CBD arms, the pooled proportions were 7.4% for enzyme elevations and 3.0% for drug-induced liver injury. High doses and concurrent antiseizure medicines were identified as risk factors, and no severe cases were reported. A pooled estimate summarizes included trials; it is not one person's predicted risk.
A laboratory result is a signal, not a diagnosis
ALT and AST are measured enzymes. Their elevation can flag possible liver stress or injury, but the number must be interpreted with timing, symptoms, other laboratory values, other medicines, and the study's stopping rules. Some elevations in the approved studies resolved after CBD was stopped. The encyclopedia reports what each study measured; it does not turn one threshold into a diagnosis or personal monitoring plan.
Important limits
What can make the answer change?
- 1
Do not treat a liver-enzyme finding from one study as a universal outcome.
- 2
Do not separate CBD safety from co-medications or product formulation.
- 3
Do not use this research page as personal medical monitoring advice.
Common questions
Questions people ask
Can CBD raise liver enzymes?
Yes. Controlled studies have recorded ALT or AST elevations in some healthy adults and prescription-CBD trial participants. Frequency varied substantially by dose, population, design, and co-medications. PubMed 40622698 PubMed 33022751 PubMed 29768152
Does every CBD user develop liver problems?
No. Most participants did not cross the reported thresholds, and an observational lower-dose study found rates similar to general-population estimates. That does not erase the controlled-trial signal. PubMed 34918948 PubMed 40622698
Does CBD dose matter for liver findings?
The pooled review identified high dose as a risk factor, while individual studies at different exposures produced different rates. The evidence supports dose context, not a universal safe threshold. PubMed 36912195 PubMed 33022751
Are elevated enzymes the same as severe liver injury?
No. Enzyme elevations are laboratory signals assessed with additional criteria. The meta-analysis reported no severe drug-induced liver injury in its included trials. PubMed 36912195